Cut in pharmaceutical prices worries domestic industry

The turmoil surrounding imminent reduction of insurance drug prices is mounting in the domestic pharmaceutical industry, as the government is pushing ahead of a new drug price re-evaluation system as a means of improving the fiscal health of medical insurance to remove the bubble of drug prices.

In parallel with the detailed draft for the implementation of the new plan, the Korea Pharmaceuti...